RECRUITING

HEARTS Trial for Thoracic Cancers

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires

Official Title

The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers

Quick Facts

Study Start:2025-09
Study Completion:2029-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07132918

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age \> 18 years at the time of consent.
  2. * Dosimetric eligibility criteria met using endpoints from QUANTEC (\>10% of heart receives \> 25 Gy) as determined through rapid auto-planning
  3. * Participants with histologically or cytologically proven AJCC, 8th edition including:
  4. * Stage IIIA,IIIB, or IIIC non-operable non-small cell lung cancer
  5. * Stage I-III N0-2 disease esophageal/esophagogastric cancer
  6. * Stage II or III thymoma/thymic carcinoma
  7. * Other cancers in the thoracic region that meet the dosimetric and other clinical trial criteria.
  8. * Participants must have a definitive course of daily fractionated RT planned of at least 15 treatment fractions, typically ranging from 1.8 to 4 Gy/fraction
  1. * Definitive clinical or radiologic evidence of metastatic disease with life expectancy \<12 months
  2. * Prior thoracic radiotherapy significantly overlapping the heart region
  3. * Contraindications to MRI
  4. * Severe, active co-morbidity defined as follows: New York Heart Association Functional Classification III/IV are not eligible.

Contacts and Locations

Study Contact

Cancer Connect
CONTACT
800-622-8922
cancerconnect@uwcarbone.wisc.edu

Principal Investigator

Carri Glide-Hurst, PhD, DABR, FAAPM
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

University of Wisconsin - Madison
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Carri Glide-Hurst, PhD, DABR, FAAPM, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09
Study Completion Date2029-03

Study Record Updates

Study Start Date2025-09
Study Completion Date2029-03

Terms related to this study

Additional Relevant MeSH Terms

  • Non-Small Cell Lung Cancer (Stage III)
  • Esophageal Cancer Stage I-III
  • Esophagogastric Cancer Stage I-III
  • Thymoma and Thymic Carcinoma Stage II-III
  • Other Cancers in the Thoracic Region